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1. Introduction 
The soft corals of genus Sarcophyton (phylum Cnidaria, class 
Anthozoa, subclass Octocorallia, order Alcyonaceae, family 
Alcyoniidae) are abounded in the South China Sea, which have 
been reported to contain a variety of diterpenes, among which 
cembranes represent the most commonly encountered structural 
type. The cembranes possess a 14-membered carbocyclic 
skeleton containing one isopropyl and three methyl groups, in 
which methyl group was often oxidized to hydroxymethyl or 
carboxylic acid, further leading to the formation of lactone rings. 
This type of secondary metabolites not only display a library of 
diverse intriguing structural features, but also exhibit a wide 
spectrum of biological activities, including cytoprotective, 
cytotoxic, anti-inflammatory, and other bioactive properties,1,2 
making them attractive targets for chemical synthesis.3,4 
The soft coral Sarcophyton trocheliophorum is a widespread 
member of the coral reef in the South China Sea. Recently, as 
part of our ongoing research project aimed at discovering 
bioactive substances from Chinese marine invertebrates,5-9 we 
collected the title soft coral, off Yalong Bay, Hainan Province, 
China. Previous chemical studies on this organism by our group 
resulted in the identification of a novel class of cyclobutane-
containing diterpenoids possessing PTP1B inhibitory activity,5 
two rare sarsolenane and three capnosane diterpenes with PTP1B 
inhibitory activity.10 Inspired by the previous work, a subsequent 
detailed chemical investigation of another collection of the title 
animal was carried out, which led to the isolation of six new 
cembranolides, sarcophytonolides S – U (1 – 3) and sartrolides H 
– J (4 – 6), along with seven known related analogues 7 – 13. In 
this paper we discuss the isolation and the structural elucidation 
of all the new compounds 1 – 6 and the stereochemical study for 
compounds 1, 3, 4 and 8 – 10. For compounds 1, 3 and 4, 
solution TDDFT calculation of ECD was applied in combination 
with conformational analysis and NMR data to determine their 
relative and absolute configurations, leading to the revision of 
relative configuration of 14. The absolute configurations of 
compounds 8 – 10 were determined by the solid-state TDDFT-
ECD approach, and that of 8 was further confirmed by single-
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A series of highly oxidative new cembranoids with diverse structural features such as a dienoate 
moiety (sarcophytonolides S – U, 1 – 3) or an α,β-unsaturated ε-lactone (sartrolides H – J, 4 – 6)
were obtained from Hainan soft coral Sarcophyton trocheliophorum, along with known related 
analogues 7 – 13. It is an extremely challenging work to determine the absolute configurations 
of these metabolites. For compounds 1, 3 and 4, solution TDDFT calculation of ECD and 
specific rotation were applied in combination with conformational analysis and NMR data to 
determine their relative and absolute configurations, leading to the revision of relative 
configuration of 14. The absolute configurations of compounds 8 – 10 were determined by the 
solid-state TDDFT-ECD approach, and that of 8 was further confirmed by single-crystal X-ray 
diffraction experiment with Cu Kα radiation. In the bioassays, compound 8 exhibited not only 
moderate protein tyrosine phosphatase 1B (PTP1B) inhibitory activity (IC50 = 15.4 µM) but also 
moderate antibacterial activity against Staphylococcus aureus Newman strain (MIC50 = 250 
µM). 
2018 Elsevier Ltd. All rights reserved.
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crystal X-ray diffraction experiment with Cu Kα radiation. This 
is first time to determine the absolute configurations of 
cembranoids with an α,β-unsaturated ε-lactone using TDDFT-
ECD approach. In addition, the evaluations of their PTP1B 
inhibitory and antibacterial activities were reported herein. 
2. Results and discussion 
Freshly collected animals of S. trocheliophorum were 
immediately put at –20 oC, and kept frozen prior to extraction. 
The usual workup5 of the Et2O-soluble fraction of the acetone 
extract of the S. trocheliophorum yielded thirteen cembrane 
derivatives (1 – 13) (Fig. 1). Among them, seven known 
compounds were readily identified as deacetylemblide (7),11 
4Z,12Z,14E-sarcophytolide (8),12 sarcrassin D (9),13 emblide 
(10),11 sarcophytonolide A (11),14 (E,E,E)-7,8-epoxy-l-isopropyl-
4,8,12-trimethylcyclotetradeca-l,3,11-triene (12),15 and 
(4Z,8S,9R,12E,14E)-9-hydroxy-1-isopropyl-8,12-
dimethyloxabicyclo[9.3.2]-hexadeca-4,12,14-trien-18-one (13),12 
respectively, by comparison of their spectral data with those 
reported in the literature 
3
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Fig. 1. The structures of compounds 1−15. 
 
A preliminary MS and 1H NMR analysis revealed that six new 
compounds 1 – 6 should share a cembrane framework. The 
following careful analysis of 1H and 13C NMR data revealed that 
sarcophytonolides S – U (1 – 3) possessed a dienoate moiety (C-
1 – C-4 and C-18), whereas sartrolides H – J (4 – 6) had a lactone 
ring, namely an α,β-unsaturated ε-lactone (C-8 – C-12 and C-20). 
The planar structures and relative configuration of compounds 1 
– 6 have been elucidated by means of a detailed 1D and 2D NMR 
analysis aided by comparison with data of related derivatives, 
and their absolute configurations were determined by TDDFT-
ECD approach. Herein we will describe firstly the structural 
analyses of epoxidic cembranes 1 – 3 followed by those of the 
lactonic cembranes 4 – 6. 
Sarcophytonolide S (1) was isolated as colorless oil. Its 
molecular formula C21H32O4 was deduced from its HR-ESI-MS 
([M + Na]+ at m/z 371.2172). Thus, six degrees of unsaturation 
were determined for 1. Compound 1 exhibited IR absorptions 
indicative of the presence of hydroxyl and ester carbonyl 
moieties (vmax 3498, 1713 cm-1).14 An intense UV absorption at 
λmax 283 nm (log ε 3.33) indicated the presence of a dienoate 
moiety,14 which was confirmed by 1H and 13C NMR data of 1: δC 
158.1 (s, C-1), 119.5 (d, C-2), 136.6 (d, C-3), 126.2 (s, C-4), 
168.0 (s, C-18), 51.4 (q, C-1´) and δH 6.88 (d, J = 11.5 Hz, H-2), 
6.67 (d, J = 11.5 Hz, H-3), 3.77 (s, Me-1´). Its NMR spectra also 
indicated the presence of an isolated trisubstituted double bond 
[δC 118.8 (d, C-11), 137.6 (s, C-12) and δH 5.03 (td, J = 7.2, 1.2 
Hz, H-11)], a trisubstituted epoxidic ring [δC 62.7 (d, C-7), 63.5 
(s, C-8), δH 2.86 (dd, J = 6.6, 5.2 Hz, H-7)] and an oxymethine 
[δC 78.0 (d, C-9) and δH 3.16 (dd, J = 8.8, 6.1 Hz, H-9)] (see 
Experimental Section). Comparison of these data with those of 
co-isolated cembranoid sarcophytonolide A (11), previously 
reported by our group,14 suggested that 1 and 11 actually share 
the same carbon framework and they only differ in the presence 
of a hydroxyl group at C-9 of 1, in agreement with the 16 mass 
units difference. This was confirmed further by the HMBC 
correlations of Me-19/C-7, C-8, and C-9, and H-7/C-9 (Fig. 2). 
The geometry of the ∆1, ∆3, and ∆11 double bonds, were 
suggested to be the same as in 12 on the basis of the almost 
identical chemical shift values for C-1 – C-4, C-11, C-12, and C-
20 in these two compounds. The relative configuration of the 
three stereogenic centers C-7, C-8 and C-9 was tentatively 
established as (7R*,8R*,9S*) by the ROESY correlations of H-
7/H-9, H-7/Ha-6 and Me-19/Hb-6 in its ROESY spectrum (Fig. 
2). Unfortunately, the attempt to determine the absolute 
configuration of 1 through the Mosher’s method failed indeed, 
due to the insufficient amount to apply the method. 
 
Fig. 2. The 1H,1H-COSY, HMBC, and ROESY correlations of compound 1. 
 
Instead, the solution TDDFT-ECD calculation method was 
applied, the efficiency of which has been demonstrated earlier in 
the stereochemical studies of conformationally flexible 
macrolides.16,17 Since elucidation of the relative configuration of 
1 was tentative, we investigated in silico two diastereomers, the 
(7S,8S,9R)-1 and the (7S,8S,9S)-1 in order to confirm the 
assignment of the relative configuration. The initial MMFF 
(Merck Molecular Force Field) conformational analysis of 
(7S,8S,9R)-1 resulted in 300 conformers (Fig. S41), while that of 
(7S,8S,9S)-1 gave 339 conformers (Fig. S42). These geometries 
were reoptimized by various DFT methods [B3LYP/6-31G(d) in 
vacuo, B3LYP/TZVP with PCM for MeCN, B97D/TZVP16,18 
with PCM for MeCN and CAM-B3LYP/TZVP19,20 with PCM for 
MeCN] and ECD spectra were computed at the B3LYP/TZVP, 
BH&HLYP/TZVP, CAM-B3LYP/TZVP and PBE0/TZVP levels. 
Interestingly, for both diastereomers we got opposite results by 
using different sets of DFT conformers. While gas-phase 
calculations for both diastereomers suggested (S) absolute 
configuration for the chirality centers C-7 and C-8, the B97D 
functional suggested opposite absolute configuration. In the case 
of (7S,8S,9R)-1, the solvent model B3LYP and CAM-B3LYP 
reoptimizations yielded similar ECD spectra to the gas-phase 
calculations (Fig. 3), while for (7S,8S,9S)-1 the experimental 
high-wavelength intense positive Cotton effect (CE) was 
computed negative but the low-wavelength one was found 
positive at these levels (Fig. 4). 
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Fig. 3. Experimental ECD spectrum of 1 in MeCN compared with the 
Boltzmann-weighted B3LYP/TZVP PCM/MeCN spectra of the B97D/TZVP 
PCM/MeCN conformers (red line, 8 conformers over 1%) and the CAM-
B3LYP/TZVP PCM/MeCN conformers (purple line, 21 conformers over 1%) 
of (7S,8S,9R)-1. Bars represent the rotational strength values of the lowest-
energy conformers. 
 
 
Fig. 4. Experimental ECD spectrum of 1 in MeCN compared with the 
Boltzmann-weighted B3LYP/TZVP spectrum of the B3LYP/6-31G(d) 
conformers (blue line, 19 conformers over 1%), B3LYP/TZVP PCM/MeCN 
spectra of the B97D/TZVP PCM/MeCN conformers (red line, 13 conformers 
over 1%) and the CAM-B3LYP/TZVP PCM/MeCN conformers (purple line, 
26 conformers over 1%) of (7S,8S,9S)-1. Bars represent the rotational 
strength values of the lowest-energy conformers. 
 
These contradicting results derived from the rather different 
Boltzmann-distribution of the conformers estimated by the 
different methods and ECD spectra were found highly sensitive 
to the conformation of the macrocycle.16 For the configurational 
assignment of highly flexible derivatives, it is advisable and 
helpful to apply the combination of more than one chiroptical 
method.21,22 Thus conformers were also reoptimized with PCM 
for CHCl3 and optical rotation (OR) values were computed for 
the gas-phase and the PCM/CHCl3 optimized conformers.23 For 
most low-energy conformers, ECD and OR calculations 
suggested the same absolute configuration or the overall OR 
value was too small to be decisive. On the basis of the computed 
ECD spectra of the two diastereomers at the same levels, it could 
be nevertheless concluded that ECD (and also OR) is mainly 
influenced by the epoxide moiety and the 9-OH has minor 
contribution. Since the combination of ECD and OR calculations 
was not sufficient to distinguish the two diastereomers, we 
investigated the low-level DFT optimized conformers obtained at 
various levels and checked the feasibility of the experimental 
ROESY effects. Most of the low-energy conformers of 
(7S,8S,9S)-1 would not give ROE effect between H-7 and H-9 
because of the large interatomic distance (see global minima on 
Fig. S42 as reference), and this is also true for most of the B97D 
optimized geometries of the other diastereomer (Fig. S41a). The 
ROESY correlations were in agreement with the conformational 
distribution of the B3LYP gas-phase, solvent model and CAM-
B3LYP reoptimization of (7S,8S,9R)-1 (Fig. S41b) and thus the 
(7S,8S,9R) absolute configuration was suggested for 1. This 
assignment is also in line with the results obtained for the 
biosynthetically related compound 3 (vide infra). 
 
Table 1. 1H (400 MHz) and 13C NMR (100 MHz) data for compounds 1 – 3 
(in CDCl3). 
No 1 2 3 
 δH δC δH δC δH δC 
1  158.1 (s)  158.8 (s)  158.6 (s) 
2 6.89 (d, 11.4) 119.5 (d) 
6.23 (d, 
12.1) 120.3 (d) 
6.22 (d, 
12.0) 118.8 (d) 
3 6.67 (dt, 11.4, 1.1) 136.6 (d) 
7.70 (d, 
12.1) 134.3 (d) 
7.60 (d, 
11.9) 136.5 (d) 
4  126.2 (s)  127.8 (s)  127.6 (s) 
5a 2.55 (7.3, 
2.9) 
30.7 (t) 2.60 (m) 23.2 (t) 2.63 (m) 23.6 (t) 
5b  2.56 (m,)  2.60 (m)  
6a 1.95 (m) 26.6 (t) 2.06 (m) 27.1 (t) 1.90 (m) 26.8 (t) 
6b 1.76 (m)  1.58 (m)  1.68 (m)  
7 
2.86 (dd, 
6.6, 5.1) 62.7 (d) 
2.86 (dd, 
9.7, 3.5) 60.6 (d) 2.65 (t, 5.6) 62.7 (d) 
8  63.5 (s)  60.9 (s)  61.0 (s) 
9a 3.16 (dd, 
8.7, 6.0) 
78.0 (d) 1.81 (m) 36.1 (t) 1.65 (m) 36.2 (t) 
9b  1.48 (m)  1.18 (m)  
10a 2.33 (m) 31.6 (t) 2.15 (m) 24.2 (t) 2.16 (m) 23.9 (t) 
10b  2.02 (m)  2.02 (m)  
11 5.03 (td, 7.1, 1.2) 118.8 (d) 
6.80 (t, 
7.6) 142.5 (d) 
6.59 (dd, 
7.6, 4.2) 144.4 (d) 
12  137.6 (s)  132.3 (s)  130.0 (s) 
13a 2.27 (m) 39.1 (t) 2.61 (m) 27.6 (t) 2.81 (m) 26.9 (t) 
13b 2.10 (m)  2.43 (m)  2.42 (m)  
14a 2.38 (m) 27.3 (t) 2.40 (m) 29.8 (t) 2.67 (m) 28.8 (t) 
14b 2.33 (m)  2.27 (m)  2.34 (m)  
15 2.39 (m) 35.3 (d) 3.19 (m) 29.7 (d) 2.00 (m) 36.7 (d) 
16 1.07 (d, 6.8) 22.0 (q) 
0.94 (d, 
6.8) 20.3 (q) 0.98 (d, 6.8) 22.2 (q) 
17 1.07 (d, 6.8) 21.7 (q) 
1.00 (d, 
6.8) 21.2 (q) 1.07 (d, 6.8) 20.7 (q) 
18  168.0 (s)  168.7 (s)  168.5 (s) 
19 1.27 (s) 10.7 (q) 1.17 (s) 17.9 (q) 1.10 (s) 16.8 (q) 
20 1.66 (d, 0.9) 16.9 (q)  168.0 (s)  167.7 (s) 
1´ 3.77 (s) 51.4 (q) 3.76 (s) 51.8 (q) 3.74 (s) 51.8 (q) 
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2´   3.74 (s) 51.8 (q) 3.76 (s) 51.7 (q) 
 
Sarcophytonolide T (2), a colorless oil, had the same 
molecular formula C22H32O5 as that of sarcophytonolides B14 and 
O24, established by HR-ESI-MS ([M + Na]+ at m/z 399.2172). 
Analysis of the NMR data for 2 (Table 1) revealed the presence 
of the same functionalities as that of sarcophytonolide B, such as 
a dienoate moiety [δC 168.5 (s, C-18), 51.8 (q, C-1´), 158.8 (s, C-
1), 120.3 (d, C-2), 134.3 (d, C-3), 127.8 (s, C-4), and δH 3.76 (s, 
Me-1´), 6.23 (d, J = 12.1 Hz, H-2), 7.70 (d, J = 12.1 Hz, H-3)], 
an α,β-conjugated methyl ester [δC 167.7 (s, C-20), 51.8 (q, C-2´), 
142.5 (d, C-11), 132.3 (s, C-12), and δH 3.74 (s, Me-2´), 6.80 (t, J 
= 7.6 Hz, H-11)], an epoxide moiety [δC 60.6 (d, C-7), 60.9 (s, C-
8), and δH 2.86 (dd, J = 9.7, 3.5 Hz, H-7)]. The detailed 
inspection of 2D NMR spectra (Fig. 5) revealed that 2 also 
shared the same carbon skeleton with sarcophytonolide B.14 The 
NOE interactions of H-2/Hb-14 and H-3/H-15 together with the s-
trans orientation of H-2 and H-3 (JH-2,H-3 = 12.1 Hz) indicated a 
(Z) configuration for ∆1 and an E-configuration for ∆3. The E-
configuration for ∆11 was deduced from the ROESY correlation 
of Ha-10/Ha-13 (Fig. 5). Thus, the geometry of the three double 
bonds within the cembrane ring of 2 is the opposite to that of 
sarcophytonolides B and O. Experimental ECD spectrum of 2 
showed only weak CEs, which were not suitable for an 
unambiguous TDDFT-ECD study and due to the conformational 
flexibility, the +42 specific rotation value could not be safely 
used to elucidate absolute configuration either. It can only 
suggest the same absolute configuration for C-7 and C-8 chirality 
centers than in 1 and 3. Based on biosynthetic considerations, the 
related 1 – 3 are homochiral for the corresponding chirality 
centers, and thus (7S,8S)-2 absolute configuration could be 
tentatively assigned. 
3
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Fig. 5. 1H,1H-COSY, HMBC, and ROESY correlations of compound 2. 
 
Sarcophytonolide U (3) was isolated as colorless oil. Its 
molecular formula C22H32O5 was deduced from the quasi-
molecular ion at m/z 399.2176 in the HR-ESI-MS. Thus, seven 
degrees of unsaturation were determined for 3. Its IR [vmax 1716, 
1636 cm-1], NMR signals [δC 168.5 (s, C-18), 167.7 (s, C-19), 
51.8 (q, C-1´), 51.7 (q, C-2´) and δH 3.74 (s, Me-1´), 3.76 (s, Me-
2´)], and UV [λmax (log ε) 286 (3.97), 238 (3.82) nm] suggested 
the presence of two α,β-unsaturated methyl ester moieties. NMR 
signals also revealed the presence of three trisubstituted double 
bonds [δC 158.6 (s, C-1), 118.8 (d, C-2), 136.5 (d, C-3), 127.6 (s, 
C-4), 144.4 (d, C-11), 130.0 (s, C-12) and δH 6.22 (d, J = 12.0 Hz, 
H-2), 7.60 (d, J = 11.9 Hz, H-3), 6.59 (t, dd = 7.6, 4.2 Hz, H-11)]; 
an epoxymethine [δC 62.7 (d, C-7) and δH 2.65 (t, J = 5.6 Hz, H-
7)]; an epoxyde quaternary carbon [δC 61.0 (s, C-8)]; an 
isopropyl group [δH 0.98 (d, J = 6.8 Hz, Me-16), 1.07 (d, J = 6.8 
Hz, Me-17), 2.00 (1H, m, H-15)]; and a methyl group [δH 1.10 (s, 
Me-19)] (Table 1). The NMR data of 3 were almost identical 
with those of sarcrassin A,13 one cembrane diterpenoid 
previously isolated from the Hainan soft coral Sarcophyton 
crassocaule. However, the sign of the [α]22D  value of 3 [+355.5 (c 
= 0.11, CHCl3)] had opposite sign to that of sarcrassin A {[α]20D  –
6.3 (c = 0.208, CHCl3)} with significantly different magnitude. It 
is essential to point out that there is a misprint or mistake for the 
13C NMR data of C-8 in sarcrassin A (δC 66.8).13 The chemical 
shift of the epoxidic quaternary carbon C-8 of cembranes from 
the genus Sarcophyton was usually observed in the range of δC 
59.0 – 64.0 ppm, and the remarkably difference between the 
chemical shifts of C-7 and C-8 in sarcrassin A (∆ 4.7 ppm) is not 
justified.1,2 Compared with structurally closely related sarcrassin 
B reported in the same paper,13 13C chemical shift of C-8 of 
sarcrassin A may have to be shifted to δC 60.8 or 61.8 reasonably, 
which is similar to that of 3. 
 
Fig. 6. Experimental ECD spectrum of 3 in MeCN compared with the 
BH&HLYP/TZVP ECD spectrum computed for the B3LYP/6-31G(d) in 
vacuo conformers of (7R,8R)-3. Bars represent computed rotational strengths 
of the lowest-energy conformer. 
 
In order to determine the absolute configuration of 3, the same 
calculation protocol was pursued as for 1. The conformational 
analysis was carried out with DFT reoptimizations at B3LYP/6-
31G(d) in vacuo (Fig. S43), B3LYP/TZVP PCM/MeCN and 
B97D/TZVP PCM/MeCN levels and ECD calculations with 
B3LYP, BH&HLYP and PBE0 functionals on the arbitrarily 
chosen (7R,8R)-3. Despite the markedly lower conformational 
flexibility (88 MMFF conformers) of 3, ECD spectra computed 
with various functionals for the different sets of DFT optimized 
geometries were rather versatile. The characteristic 280 nm 
positive experimental ECD transition was reproduced with a 
negative sign in all the combinations suggesting (7S,8S) absolute 
configuration but acceptable overall mirror image agreement was 
found only by the BH&HLYP/TZVP level ECD calculations 
performed on the B3LYP/6-31G(d) in vacuo conformers (Fig. 6). 
Many other combinations showed partial agreement and partial 
mirror-image agreement simultaneously indicating a possible 
Boltzmann-population error, which seemed decisive for the 
computed ECD curves. OR values were also computed at the 
same levels as for 1. All the 3 applied levels for all 3 sets of DFT 
reoptimizations resulted in large negative average values and all 
solvent model calculations yielded only conformers with 
negative OR value over 1.5% population, verifying the ECD 
results and allowing the unambiguous elucidation of the absolute 
configuration as (7S,8S). 
The HR-ESI-MS data for sartrolide H (4) indicated the 
molecular formula C21H32O5, differing from that of sartrolide C 
(14)25 in a CH2 residue. Analysis of its spectral data clearly 
indicated that two molecules shared the presence of an (E)-C=C 
bond [δC 152.5 (s, C-1), 119.6 (d, C-2), and δH 5.38 (1H, d, J = 
9.5 Hz, H-2)], an epoxide moiety [δC 63.1 (s, C-4), 60.2 (d, C-5), 
and δH 2.98 (1H, dd, J = 10.4, 4.3 Hz, H-5], a hydroxymethine 
[δC 69.1 (d, C-7) and δH 4.08 (1H, d, J = 11.6 Hz, H-7)], and an 
α,β-unsaturated ε-lactone [δC 166.3 (s, C-20), 141.2 (d, C-11), 
132.4 (s, C-12), 82.9 (s, C-8), and δH 6.21 (t, J = 4.6 Hz, H-11)] 
(see Experimental Section). Careful comparison of NMR spectra 
of 4 and 14 located the differences at C-3, where an –OMe group 
in 4 linked instead of an –OH group in 14, which was further 
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shift of C-3 was downfield shifted (from δC 66.7 to 75.4).26 The 
pattern of coupling constants and ROESY correlations detected 
for 4 exactly paralleled with those of 14, thus indicating that the 
two molecules shared the same relative configuration. Since the 
use of methanol was avoided during the entire 
extraction/purification procedure of the organism, an artifact 
nature of the methyl ether group present in 4 can be excluded. 
 
Fig. 7. The 1H,1H-COSY and HMBC correlations of compound 4. 
 
Reoptimization of the 81 MMFF conformers of 
(3S,4R,5R,7R,8R)-4 at B3LYP/6-31G(d) in vacuo, B97D/TZVP 
PCM/MeCN and CAM-B3LYP/TZVP PCM/MeCN levels 
resulted in 3, 15 and 25 conformers over 1%, respectively (Fig. 
S44). Both the gas-phase and solvent model ECD calculations  
(Fig. S45) gave very bad and contradictory agreement with the 
experimental ECD and low-energy conformers were not in line 
with the NOE correlations found in the earlier work25 for 14 
(especially H-3/H-14a, H-3/H-6b and H-7/Me-19 seemed to be 
difficult to be present simultaneously). It seems that due to the 
flexibility of the macrocycle, NOE correlations of H-3 are not 
decisive for the relative configuration and thus 
(3R*,4R*,5R*,7R*,8R*) relative configuration may be also 
possible. Indeed, the 79 MMFF conformers reoptimized at the 
above three levels gave low-energy conformers (Fig. S46) in 
accordance with the characteristic NOE correlations reported for 
14 and ECD calculations computed for each sets of conformers at 
various levels gave univocally moderate to good agreement with 
the experimental ECD spectrum (Fig. 8) allowing to modify the 
relative configuration of 14 and elucidate the absolute 
configuration of 4 as (3R,4R,5R,7R,8R). It is interesting to note 
that B97D functional performed the best for DFT optimization 
while it had problems for 1 and 3 underlining that there is no 
superior level of theory for computing chiroptical parameters and 
more than one level is recommended to test for flexible 
systems.16,27 
 
Fig. 8. Experimental ECD spectrum of 4 in MeCN (black) compared with the 
Boltzmann-weighted B3LYP/TZVP PCM/MeCN ECD spectrum of 
(3R,4R,5R,7R,8R)-4 (red) computed for the B97D/TZVP PCM/MeCN 
conformers. Bars represent computed rotational strengths of the lowest-
energy conformer. 
 
Table 2. 1H (400 MHz) and 13C NMR (100 MHz) data for compounds 5 
and 6 (in CDCl3). 
No 5 6 
δH δC δH δC 
1  75.9 (s)  74.7 (s) 
2 5.48 (d, 16.6) 134.6 (d) 5.71 (d, 15.7) 134.5 (d) 
3 5.53 (d, 16.6) 132.9 (d) 5.59 (d, 15.7) 133.9 (d) 
4  73.4 (s)  74.0 (s) 
5a 1.73 (m) 35.2 (t) 1.70 (m, Ha) 35.3 (t) 
5b 1.67 (m)  1.64 (m, Hb)  
6a 1.84 (m) 25.1 (t) 1.80 (m, Ha) 24.0 (t) 
6b 1.66 (m)  1.69 (m, Hb)  
7 5.29 (d, 9.9) 71.6 (d) 5.47 (d, 10.6, 1.8) 73.5 (d) 
8  82.9 (s)  82.7 (s) 
9a 2.02 (m) 36.1(t) 2.08 (m, Ha) 34.1 (t) 
9b 1.98 (m)  1.98 (m, Hb)  
10a 2.79 (m) 24.2 (t) 2.85 (m, Ha) 27.2 (t) 
10b 1.96 (m)  1.43 (m, Hb)  
11 6.48 (t, 4.5) 141.9 (d) 6.34 (t, 4.5) 143.6 (d) 
12  133.8 (s)  134.0 (s) 
13a 3.05 (t, 13.0) 30.6 (t) 2.93 (t, 13.7, Ha) 31.8 (t) 
13b 2.19 (m)  2.20 (m, Hb)  
14a 1.88 (m) 39.0 (t) 1.98 (m, Ha) 37.8 (t) 
14b 1.84 (m)  1.81 (m, Hb)  
15 1.69 (m) 37.5 (d) 1.77 (m) 39.8 (d) 
16 0.86 (d, 6.8) 17.3 (q) 0.85 (d, 6.8) 16.9 (q) 
17 0.80 (d, 6.8) 16.3 (q) 0.88 (d, 6.8) 16.8 (q) 
18 1.24 (s) 32.3 (q) 1.23 (s) 32.2 (q) 
19 1.39 (s) 23.7 (q) 1.37 (s) 23.4 (q) 
20  168.5 (s)  168.5 (s) 
1´  171.4 (s)  171.1 (s) 
2´ 2.10 (s) 21.3 (q) 2.12 (s) 21.3 (q) 
 
Sartrolide I (5), a colorless oil, had the same molecular 
formula C22H32O5 as that of sartrolide D (15),25 according to the 
HR-ESI-MS ([M + Na]+ at m/z 415.2076), which was 
corresponding to an additional C2H2O unit compared to 15 and 
indicating one degree of unsaturation more than 15. Inspection of 
1H and 13C NMR spectral data of 5 (Table 2), aided by 2D NMR 
experiments (Fig. 9), indicated the presence of an α,β-unsaturated 
ε-lactone moiety (C-8–C-12 and C-20), an (E)-C=C bond (C-2 
and C-3), and two oxygenated quaternary carbons (C-1 and C-4), 
which were the same as in 15. Careful comparison of the NMR 
data of 5 and 15 revealed that the only difference between them 
resided in the replacement of the –OH group at C-7 with an –
OAc group, as clearly indicated by the significant downfield shift 
of H-7 (from δH 4.44 in 15 to 5.29 in 5) and by its HMBC cross-
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peak of H-7/C-1´ (Fig. 9). Its ROESY cross-peaks of H-3/Me-
16 and Me-18 revealed that the isopropyl group and Me-18 were 
co-facial (α) (Fig. 9). The pattern of coupling constants and 
NOESY correlations detected for the residue partial structure of 5 
(Fig. 9) were similar to those of 15, thus indicating that the two 
molecules shared the same relative configurations for the 
corresponding chiral centers. Hence, the isolate 5 was the 
corresponding 7-O-acetyl derivative of 15. Unfortunately, 
acetylation of 15 using acetic anhydride/pyridine or 
dichloromethane was failed, probably due to the steric hindrance 
around the secondary OH group. 
 
Fig. 9. The 1H,1H-COSY, HMBC, and ROESY correlations of compound 5. 
 
Sartrolide J (6) possessed the same molecular formula 
C22H34O6 as that of sartrolide I (5), as deduced from the quasi-
molecular ion at m/z 417.2269 in the HR-ESI-MS. Inspection of 
NMR data of 6 (Table 2) revealed that the planar structure of 6 
should be the same as that of 5. The ROESY correlations of H-
2/Me-17 and H-3/Me-18 revealed different orientations of the 
isopropyl group and Me-18 in 6, which were different from those 
of 5. Referred to the above mentioned general rule,28,29 the 
configuration at C-1 of 6 was tentatively assigned as α, and 
subsequently β-orientation for Me-18. Hence, the isolate 6 was 
the corresponding 7-O-acetyl derivative of 4-epi-15. 
 
Fig. 10. Perspective drawing of the X-ray structure of compound 8. 
 
 
Due to the flexibility of the cembrane, it is an extremely 
challenging work to determine the absolute configurations of 
these metabolites. Since our attempts to upgrade the relative 
configurations around the 14-membered cembrane rings of 
sarcophytonolides S – U (1 – 3) and sartrolides H – J (4 – 6) to 
the absolute ones through the Mosher’s method had failed, we 
tried to get crystals for application of X-ray crystallography 
along with the solution TDDFT approach. Given the higher 
amounts available, these attempts proved to be successful for the 
three known compounds, 4Z,12Z,14E-sarcophytolide (8), 
sarcrassin D (9), emblide (10), which were re-crystallized from 
methanol. Among them, the absolute configurations of 9 and 
emblide 10 was regained in this research, which had been 
elucidated by single-crystal X-ray diffraction experiment with Cu 
Kα (λ = 1.54178 Å) radiation previously by our group.25 
Similarly, the absolute configuration of 8 was assigned to be 8R, 
suggested by the Flack parameter [–0.03(17)] (Fig. 10). 
Noteworthy, the three compounds 8 – 10 share the R 
configuration at C-8, the joining point of the α,β-unsaturated ε-
lactone moiety within the cembrane ring. 
 
Fig. 11. Solution (acetonitrile, grey curve) and solid-state (black curve) ECD 
spectra of (+)-(8R)-4Z,12Z,14E-sarcophytolide (8) compared with the 
computed BH&HLYP/TZVP (blue) spectrum calculated for X-ray geometry 
of (8R)-8. Bars represent computed rotational strengths. 
 
 
Fig. 12. Solution (acetonitrile, grey curve) and solid-state (black curve) ECD 
spectra of (+)-(7S,8R)-sarcrassin D (9) compared with the computed 
BH&HLYP/TZVP (blue) spectrum calculated for X-ray geometry of (7S,8R)-
9. Bars represent computed rotational strengths. 
 
 
Fig. 13. Solution (acetonitrile, grey curve) and solid-state (black curve) ECD 
spectra of (+)-(7S,8R)-emblide (10) compared with the computed 
BH&HLYP/TZVP (blue) spectrum calculated for X-ray geometry of (7S,8R)-
10. Bars represent computed rotational strengths. 
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were confirmed by the solid-state TDDFT-ECD approach. The 
solid-state TDDFT-ECD method is a powerful tool, and has been 
tested and utilized for the configurational assignment of 
numerous natural products.30-32 The ECD spectra of (+)-8, (+)-9, 
and (+)-10 were recorded in both acetonitrile solution and as KCl 
disk, which showed similar profiles (Fig. 11 – 13), suggesting 
that similar conformers are prevalent in solution and the solid-
state (For descriptions referring characteristic bands in their ECD 
spectra see Text S1). The X-ray geometries of compounds 8 – 10 
were optimized at the B3LYP/6-31G(d) DFT level in vacuo (Fig. 
S47 – 49) for the solid-state TDDFT-ECD method,. These 
structures were employed for TDDFT calculations with various 
functionals (B3LYP, BH&HLYP and PBE0) and TZVP basis set 
to check the consistency of the calculations. The CD spectrum 
calculated with the TDDFT method at the BH&HLYP/TZVP 
level, using as input geometry the X-ray coordinates for 8 – 10 
with (8R), (7S,8R) and (7S,8R) configurations, respectively, is 
shown in Fig. 11 – 13. It clearly reproduced well the shapes of 
the main experimental bands, except for some intensity 
overestimation. Thus the absolute configurations of (+)-
4Z,12Z,14E-sarcophytolide (8), (+)-sarcrassin D (9), and (+)-
emblide (10) were determined as (+)-(8R)-8, (+)-(7S,8R)-9, and 
(+)-(7S,8R)-10. 
Compounds 1 – 8 were tested for their inhibitory activity 
against protein tyrosine phosphatase 1B (PTP1B), a key target for 
the treatment of Type-II diabetes and obesity.33 The result 
showed that compounds 4 and 8 exhibited moderate PTP1B 
inhibitory activity (IC50’s = 19.9 ± 3.13 and 15.4 ± 1.11 µM, 
respectively), of which compound 8 exhibited the strongest 
inhibitory activity, but less than that of positive control oleanolic 
acid (IC50 = 2.6 µM). In addition, compound 8 also exhibited 
moderate antibacterial activity against Staphylococcus aureus 
Newman strain (MIC50 = 250 µM). 
Due to the scarcity of the new products, biomimetic total 
synthesis and chemical correlation should be conducted in future 
to understand their biosynthetic origins and their biological role 
in the life cycle of the soft coral, which would be helpful for 
further specific pharmacological studies. 
In conclusion, thirteen cembrane derivatives (1 – 13) with 
diverse structural features were isolated from animals of S. 
trocheliophorum. Structurally, these cembranoids can be 
classified into two subclasses: one subclass consisited of 
sarcophytonolides S – U (1 – 3) which possessed a dienoate 
moiety including (C-1 – C-4 and C-18), whereas the other 
subclass comprised by sartrolides H – J (4 – 6) which had an α,β-
unsaturated ε-lactone (C-8 – C-12 and C-20). Our results provide 
further evidences about the chemical diversity of this distinct 
group of diterpenes produced by the title animals. For 
compounds 1, 3 and 4, solution TDDFT calculation of ECD and 
specific rotation was applied in combination with conformational 
analysis and NMR data to determine the relative and absolute 
configuration, leading to the revision of relative configuration of 
14. The absolute configurations of compounds 8 – 10 were 
determined by the solid-state TDDFT-ECD approach, and that of 
8 was further confirmed by single-crystal X-ray diffraction 
experiment with Cu Kα radiation. This is first time to determine 
the absolute configurations of above cembranoids using TDDFT-
ECD approach. Among the isolates, compounds 4 and 8 
exhibited moderate PTP1B inhibitory activity, and compound 8 
also exhibited moderate antibacterial activity. 
3. Experimental section 
3.1. General experimental procedures 
Optical rotations were measured on a Perkin-Elmer 241MC 
polarimeter. UV spectra were recorded on a Varian Cary 300 Bio 
spectrophotometer. IR spectra were recorded on a Nicolet-Magna 
FT-IR 750 spectrometer. NMR spectra were measured on either a 
Bruker DRX-500 or a Bruker DRX-400 spectrometer with the 
residual CHCl3 (δH 7.26 ppm, δC 77.0 ppm) as an internal 
standard. ESIMS and HRESIMS spectra were recorded on a Q-
TOF Micro LC-MS-MS mass spectrometer. Reversed phase 
HPLC (Agilent 1100 series liquid chromatography using a VWD 
G1314A detector at 210 nm and a semipreparative ODS-HG-5 [5 
µm, 10 mm (i.d.) × 25 cm] column) was also employed. 
Commercial Si gel (Qing Dao Hai Yang Chemical Group Co., 
200-300 and 400-600 mesh) and Sephadex LH-20 (Amersham 
Biosciences) was used for column chromatography, and 
precoated Si gel plates (Yan Tai Zi Fu Chemical Group Co., G60 
F-254) were used for analytical TLC. X-ray diffraction studies 
were carried out on a Bruker APEX2 CCD diffractometer. 
3.2. Biological material 
The specimens of S. trocheliophorum, identified by Prof. H. 
Huang of the South China Sea Institute of Oceanology, Chinese 
Academy of Sciences (CAS), were collected by scuba at Yalong 
Bay, Hainan Province, China, in February 26, 2006, at a depth of 
−20 m, and were frozen immediately after collection. A voucher 
specimen is available for inspection at the Shanghai Institute of 
Materia Medica, CAS, under registration No. YAL-62. 
3.3. Extraction and isolation 
The frozen animals (301 g, dry weight) were cut into pieces 
and extracted exhaustively with Me2CO at room temperature (3 × 
1.5 l, 15 min in ultrasonic bath). The organic extract was 
evaporated to give a brown residue, which was partitioned 
between Et2O and H2O. The Et2O solution was concentrated 
under reduced pressure to give a dark brown residue (3.5 g), 
which was fractionated by gradient Si gel (200-300 mesh) 
column chromatography (CC) (0 → 100% Et2O in petroleum 
ether (PE)), yielding twenty-one fractions (A – U). Each of 
fractions J and M was subjected to silica gel (400-600 mesh) CC 
(PE/Et2O 25:1 and PE/Me2CO 30:1, respectively) to give 11 
(13.8 mg) and 12 (23.0 mg), respectively. Fraction N was 
purified by CC (Sephadex LH-20, PE/CHCl3/MeOH 2:1:1), 
followed by CC (silica gel (400-600 mesh), PE/Me2CO, 10:1)) to 
afford two sub-fractions N1 and N2. Sub-fraction N1 was 
successively separated by reversed-phase HPLC [semi-prep. 
ODS-HG-5 (5 µm, 250 × 9.4 mm), MeCN/H2O (67:33), 2.0 
ml/min] to afford 8 (12.0 mg; tR 39.1 min). Similarly, 2 (10.2 mg; 
tR 27.3 min) and 3 (6.6 mg; tR 29.1 min) were obtained from sub-
fraction N2 by reversed-phase HPLC [semi-prep. ODS-HG-5 (5 
µm, 250 × 9.4 mm), MeCN/H2O (70:33), 2.0 ml/min]. Fraction O 
was further divided into three sub-fractions O1, O2, and O3 (56.1 
mg, 107.2 mg, and 72.7 mg, respectively) by CC (sillica gel 
(400-600 mesh), PE/Et2O, 2:1 → 1:1)). Sub-fraction O2 was then 
purified by reversed-phase HPLC [semi-prep. ODS-HG-5 (5 µm, 
250 × 9.4 mm), MeCN/H2O (80:20), 2.0 ml/min] yielding 9 (26.3 
mg; tR 17.0 min), and 10 (54.7 mg; tR 15.6 min) and a mixture of 
residue, from which 1 (1.9 mg; tR 22.5 min) was obtained by the 
further purification using reversed-phase HPLC [semi-prep. 
ODS-HG-5 (5 µm, 250 × 9.4 mm), MeOH/H2O (85:15), 2.0 
ml/min]. Fraction P was subjected to a column of Sephadex LH-
20 eluting with PE/CHCl3/MeOH (2:1:1) to give five sub-
fractions P1–P5 (13.9 mg, 43.7 mg, 59.9 mg, 39.8 mg, 19.3 mg, 
respectively). Sub-fraction P4 was successively separated by 
reversed-phase HPLC [semi-prep. ODS-HG-5 (5 µm, 250 × 9.4 
mm), MeCN/H2O (70:30), 2.0 ml/min] yielding 4 (4.3 mg; tR 9.8 
min) and 13 (1.1 mg; tR 20.4 min). Two sub-fractions Q1 and O2 
(84.3 mg, 56.9 mg, respectively) were got from fraction Q by CC 
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(Sephadex LH-20, PE/CHCl3/MeOH 2:1:1). Sub-fraction Q1 
was further purified by reversed-phase HPLC [semi-prep. ODS-
HG-5 (5 µm, 250 × 9.4 mm), MeCN/H2O (53:47), 2.0 ml/min] to 
6 (2.9 mg; tR 14.6 min) and 7 (7.5 mg; tR 34.2 min). Similarly, 5 
(4.3 mg; tR 23.3 min) was obtained from sub-fraction Q2 by 
reversed-phase HPLC [semi-prep. ODS-HG-5 (5 µm, 250 × 9.4 
mm), MeCN/H2O (45:55), 2.0 ml/min]. 
3.3.1 Sarcophytonolide S (1): colorless oil. [α]20D  = +112.0 (c = 
0.08, CHCl3). UV (MeOH): 283 (3.33). ECD {MeCN, λ [nm] 
(∆ε), c 0.153 mM}: 313sh (+0.06), 283 (+0.34), 267sh (+0.26), 
223sh (+0.43), 209 (+0.96), 200 (+1.14). IR (KBr): 3498, 2958, 
2930, 1713, 1636, 1070. 1H- and 13C-NMR, see Table 1. ESI-MS: 
371.3 ([M + Na]+). HR-ESI-MS: 371.2172 ([M + Na]+, 
C21H32NaO4+; calc. 371.2198). 
3.3.2 Sarcophytonolide T (2): colorless oil. [α]20D  = +42.5 (c = 
0.12, CHCl3). IR (KBr): 2958, 1714, 1629, 1037, 940, 745. 1H- 
and 13C-NMR, see Table 1. ESI-MS: 399.3 ([M + Na]+). HR-ESI-
MS: 399.2146 ([M + Na]+, C22H32NaO5+; calc. 399.2147). 
3.3.3 Sarcophytonolide U (3): colorless oil. [α]22D  = +355.5 (c 
= 0.11, CHCl3). UV (CHCl3): 238 (3.82), 286 (3.97). ECD 
{MeCN, λ [nm] (∆ε), c 0.147 mM}: 292sh (+0.87), 282 (+1.00), 
269sh (+0.69), 237 (+0.32), 222sh (-0.11), 213 (-0.33) , 203 (-
0.55) , 195sh (-0.25). IR (KBr): 2957, 1716, 1634, 1076, 761. 1H- 
and 13C-NMR, see Table 1. ESI-MS: 399.3 ([M + Na]+). HR-ESI-
MS: 399.2176 ([M + Na]+, C22H32NaO5+; calc. 399.2147). 
3.3.4 Sartrolide H (4): Colorless oil. [α]20D  = +78 .0 (c = 0.11, 
CHCl3). ECD {MeCN, λ [nm] (∆ε), c 0.122 mM}: 314sh (+0.12), 
296 (+0.26), 270sh (-0.43), 262 (-0.60), 232 (+2.34), 204 (+6.34), 
199sh (+5.44). IR (KBr): 3463, 2924, 1670, 1640, 1067, 947, 751. 
1H-NMR (CDCl3, 400 MHz): δ 5.38 (1H, d, J = 9.6 Hz, H-2), 
3.62 (1H, d, J = 9.6 Hz, H-3), 2.98 (1H, dd, J = 10.4, 4.3 Hz, H-
5), 2.25 (1H, m, Ha-6), 1.60 (1H, ddd, J = 14.7, 10.5, 2.1 Hz, Hb-
6), 4.08 (1H, d, J = 12.5 Hz, H-7), 2.18 (1H, m, Ha-9), 2.04 (1H, 
m, Hb-9), 2.49 (1H, m, H2-10), 6.21 (1H, t, J = 4.5 Hz, H-11), 
3.06 (1H, d, J = 14.1 Hz, Ha-13), 2.29 (1H, m, Hb-13), 2.61 (1H, t, 
J = 13.9 Hz, Ha-14), 2.21 (1H, m, Hb-14), 2.46 (1H, m, H-15), 
1.07 (3H, d, J = 7.3 Hz, Me-16), 1.09 (3H, d, J = 7.3 Hz, Me-17), 
1.41 (3H, s, Me-18), 1.38 (3H, s, Me-19), 3.26 (3H, s, Me-1´). 
13C-NMR (CDCl3, 100 MHz): δ 152.5 (s, C-1), 119.6 (d, C-2), 
75.4 (d, C-3), 63.1 (s, C-4), 60.2 (d, C-5), 30.4 (t, C-6), 69.1 (d, 
C-7), 82.9 (s, C-8), 34.6 (t, C-9), 26.7 (t, C-10), 141.2 (d, C-11), 
132.4 (s, C-12), 33.8 (t, C-13), 28.1 (t, C-14), 30.3 (d, C-15), 
23.2 (q, C-16), 20.9 (q, C-17), 17.8 (q, C-18), 22.7 (q, C-19), 
166.3 (s, C-20), 56.2 (q, C-1´). ESI-MS: 387.2 ([M + Na]+). HR-
ESI-MS: 387.2158 ([M + Na]+, C21H32NaO5+; calc. 387.2147). 
3.3.5 Sartrolide I (5): Colorless oil. [α]20D  = +18.7 (c = 0.11, 
CHCl3). IR (KBr): 3478, 2927, 1710, 1667, 1635, 1065, 948 750. 
1H- and 13C-NMR, see Table 2. EI-MS: 417.3 ([M + Na]+). HR-
ESI-MS: 417.2236 ([M + Na]+, C22H34NaO6+; calc. 417.2253). 
3.3.6 Sartrolide J (6): Colorless oil. [α]20D  = +12.5 (c = 0.09, 
CHCl3). IR (KBr): 3483, 2929, 1707, 1664, 1639, 1069, 944, 753. 
1H- and 13C-NMR: Table 2. ESI-MS: 417.3 (100, [M + Na]+). 
HR-ESI-MS m/z 417.2269 ([M + Na]+, C22H34NaO6+; calc. 
417.2253). 
3.3.7 Deacetylemblide (7): Colorless oil. [α]22D  +88.0 (c = 0.11, 
CHCl3). IR (KBr): 3457, 1717, 1672, 1636, 1069, 952, 746. 13C-
NMR (CDCl3, 100 MHz): δ 155.9 (s, C-1), 120.0 (d, C-2), 135.3 
(d, C-3), 124.8 (s, C-4), 25.6 (t, C-5), 27.5 (t, C-6), 65.3 (d, C-7), 
83.3 (s, C-8), 34.4 (t, C-9), 27.0 (t, C-10), 142.3 (d, C-11), 132.1 
(s, C-12), 36.7 (t, C-13), 27.7 (t, C-14), 35.3 (d, C-15), 21.8 (q, 
C-16), 22.1 (q, C-17), 170.0 (s, C-18), 22.9 (q, C-19), 166.6 (s, 
C-20), 51.6 (q, C-1´). ESI-MS: 385.3 ([M + Na]+). 
3.3.8 4Z,12Z,14E-Sarcophytolide (8): Colorless crystals 
(MeOH). m.p. 121.3 – 122.8°. [α]22D  = +132.1 (c = 0.11, CH2Cl2). 
ECD {MeCN, λ [nm] (∆ε), c 0.268 mM}: 277sh (+4.58), 262sh 
(+15.08), 257sh (+22.53), 248sh (+39.00), 241 (+45.68), 225sh (-
19.09), 217 (-32.69), 209sh (-24.75), 192 (-18.03). ECD {(37 µg 
in 250 mg KCl), λ [nm] (Φ)}: 319 (-1.32), 285sh (+3.52), 273sh 
(+9.32), 259sh (+33.49), 250sh (+58.00), 243 (+67.10), 222sh (-
42.65), 217 (-48.59), 208sh (-35.69), 192 (-26.34). 
3.3.9 Sarcrassin D (9): Colorless crystals (MeOH). m.p. 113.5 
– 115.1°. [α]22D  = +180.1 (c 0.10, CHCl3). ECD {MeCN, λ [nm] (∆ε), c 0.149 mM}: 296sh (+4.56), 286sh (+7.50), 276 (+8.55), 
263sh (+7.77), 253sh (+6.58), 241sh (+5.47), 216 (-5.17). ECD 
{49 µg in 250 mg KCl, λ [nm] (Φ)}: 314sh (+0.61), 304sh 
(+3.86), 291sh (+9.18), 281 (+10.74), 273sh (+9.79), 245sh 
(+5.92), 242sh (+5.78), 217sh (-10.62), 211 (-11.37). 
3.3.10 Emblide (10): Colorless crystals (MeOH). m.p. 121.5 – 
123.1°. [α]20D  = +154.5 (c = 0.11, CHCl3). ECD {MeCN, λ [nm] (∆ε), c 0.270 mM}: 305sh (+4.75), 295sh (+9.67), 279 (+14.23), 
266sh (+10.78), 258sh (+5.67), 238sh (-4.34), 220 (-15.38), 
208sh (-10.71), 193sh (+5.77). ECD {58 µg in 250 mg KCl, λ 
[nm] (Φ)}: 320sh (+1.06), 297sh (+13.36), 279 (+25.67), 263sh 
(+13.86), 248sh (-3.17), 221 (-29.29), 215sh (-27.76), 205sh (-
13.33), 195sh (+9.42). 
3.4. X-ray crystallographic analysis 
Colorless blocks, C20H28O3, Mr = 316.42, monoclinic, crystal 
size 0.14 × 0.10 × 0.08 mm, space group P2(1), a = 9.7253 (2) Å, 
b = 9.2859 (2) Å, c = 10.5777 (2) Å, V = 870.44 (3) Å3, Z = 2, 
Dcalcd = 1.207 mg m−3, F000 = 344, 5713 collected reflections, 
2589 unique reflections (Rint = 0.034), final R1 = 0.0329 (wR2 = 
0.0900) for 2567 reflections with I > 2σ(I), R1 = 0.0332, wR2 = 
0.0906 for all unique data. The X-ray measurements were made 
on a Bruker APEX2 CCD X-ray diffractometer with graphite-
monochromated Cu Kα (λ =1.54178 Å) radiation at 133(2) K. 
The structure was solved by direct methods (SHELXS-97) and 
refined with full-matrix least-squares on F2 (SHELXL-97). The 
non-hydrogen atoms were refined anisotropically. All H atoms 
were located in a difference Fourier map, but they were 
introduced in calculated positions and treated as riding on their 
parent atoms [C–H = 0.93-0.97 Å, O–H = 0.82 Å, and Uiso(H) = 
1.2Ueq(C) and 1.51Ueq-(C, O)]. CCDC 920814 contains the 
supplementary crystallographic data for this compound. These 
data can be obtained free of charge from Cambridge 
Crystallographic Data Centre via www.ccdc.can.ac.uk/data 
request/cif. 
3.5. Computational section 
Geometry optimizations [B3LYP/6-31G(d) in vacuo, 
B3LYP/TZVP, B97D/TZVP16,18 and CAM-B3LYP/TZVP19,20 
with PCM solvent model for MeCN or CHCl3] and TDDFT 
calculations were performed with Gaussian 0934 using various 
functionals (B3LYP, BH&HLYP, CAM-B3LYP and PBE0) and 
TZVP basis set. ECD spectra were generated as the sum of 
Gaussians35 with 4200 to 2400 cm–1 half-height width 
(corresponding to c.a. 20-12 nm at 220 nm), using dipole-
velocity computed rotational strengths. Mixed torsional/low 
mode conformational searches were carried out by means of the 
Macromodel 9.9.22336 software using Merck Molecular Force 
Field (MMFF) with implicit solvent model for CHCl3 applying a 
21 kJ/mol energy window. Boltzmann distributions were 
estimated from the B3LYP, B97D and CAM-B3LYP energies. In 
the case of the B3LYP/6-31G(d) in vacuo level ZPVE 
corrections were applied. The MOLEKEL37 software package 
was used for visualization of the results. 
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Recombinant PTP1B catalytic domain was expressed and 
purified according to a previous report.38 The enzymatic activities 
of the PTP1B catalytic domain were determined at 30 °C by 
monitoring the hydrolysis of pNPP. Dephosphorylation of pNPP 
generates product pNP, which was monitored at an absorbance of 
405 nm by the EnVision multilabel plate reader (PerkinElmer 
Life Sciences, Boston, MA). In a typical 100 µL assay mixture 
containing 50 mmol/L 3-[N-morpholino] propanesulfonic acid 
(MOPs), pH 6.5, 2 mmol/L pNPP, and 30 nmol/L recombinant 
PTP1B, activities were continuously monitored and the initial 
rate of the hydrolysis was determined using the early linear 
region of the enzymatic reaction kinetic curve. The IC50 was 
calculated with Prism 4 software (Graphpad, San Diego, CA) 
from the nonlinear curve fitting of the percentage of inhibition 
(% inhibition) versus the inhibitor concentration [I] by using the 
following equation: % Inhibition = 100/(1 + [IC50/[I]]k), where k 
is the Hill coefficient. The positive control is oleanolic acid (IC50 
value is 2.56 ± 0.20 µM). 
3.7. Antibacterial activity assay 
The antimicrobial activities of natural products against 
Staphylococcus aureus Newman strain were performed by paper 
disk diffusion antimicrobial susceptibility test39 and MIC 
(Minimum Inhibitory Concentration) method, respectively. 
Zones of inhibition were measured after 24 hr of incubation at 
37ºC. For the MIC method, all the natural products were 
dissolved in DMSO (Dimethyl Sulphoxide) and diluted with 
culture broth to a concentration of 0.5 mg/mL. Further 1:2 serial 
dilutions were performed by addition of culture broth to reach 
concentrations ranging from 0.5 to 0.0156 mg/mL; 100 µL of 
each dilution were distributed in 96-well plates, as well as a 
sterility control and a growth control (containing culture broth 
plus DMSO, without natural products). Each test and growth 
control well was inoculated with 5 µL of a bacterial suspension 
(105 CFU/well). The 96-well plates were incubated at 37ºC for 24 
h. MIC of the natural products against Staphylococcus aureus 
Newman strain was defined as the lowest concentration of each 
natural product, which completely inhibited bacterial growth. 
The positive control is fosfomycin sodium (MIC50 = 137.4 µM). 
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